Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer
The role for localized radiation to treat ovarian cancer (OC) patients with locally recurrent vaginal/perirectal lesions remains unclear, though we hypothesize these patients may be salvaged locally and gain long-term survival benefit. We describe our institutional outcomes using intensity modulated...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578921001120 |
| _version_ | 1818670470621298688 |
|---|---|
| author | E.A. Johns J.A. Stanley M.D. Toboni J.K. Schwarz F. Zhang A.R. Hagemann K.C. Fuh P.H. Thaker C.K. McCourt D.G. Mutch M.A. Powell D. Khabele L.M. Kuroki |
| author_facet | E.A. Johns J.A. Stanley M.D. Toboni J.K. Schwarz F. Zhang A.R. Hagemann K.C. Fuh P.H. Thaker C.K. McCourt D.G. Mutch M.A. Powell D. Khabele L.M. Kuroki |
| author_sort | E.A. Johns |
| collection | DOAJ |
| description | The role for localized radiation to treat ovarian cancer (OC) patients with locally recurrent vaginal/perirectal lesions remains unclear, though we hypothesize these patients may be salvaged locally and gain long-term survival benefit. We describe our institutional outcomes using intensity modulated radiation therapy (IMRT) +/- high-dose rate (HDR) brachytherapy to treat this population. Our primary objectives were to evaluate complete response rates of targeted lesions after radiation and calculate our 5-year in-field control (IFC) rate. Secondary objectives were to assess radiation-related toxicities, chemotherapy free-interval (CFI), as well as post-radiation progression-free (PFS) and overall survival (OS). PFS and OS were defined from radiation start to either progression or death/last follow-up, respectively. This was a heavily pre-treated cohort of 17 recurrent OC patients with a median follow-up of 28.4 months (range 4.5–166.4) after radiation completion. 52.9% had high-grade serous histology and 4 (23.5%) had isolated vaginal/perirectal disease. Four (23.5%) patients had in-field failures at 3.7, 11.2, 24.5, and 27.5 months after start of radiation, all treated with definitive dosing of radiation therapy. Patients who were platinum-sensitive prior to radiation had similar median PFS (6.5 vs. 13.4 months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months, log-rank p = 0.05) than their platinum-resistant counterparts. Excluding patients with low-grade histology or who were treated with palliative radiation, median CFI was 14.2 months (range 4.7 – 33.0). Radiation was well tolerated with 2 (12.0%) experiencing grade 3/4 gastrointestinal/genitourinary toxicities. In conclusion, radiation to treat locally recurrent vaginal/perirectal lesions in heavily pre-treated OC patients is safe and may effectively provide IFC. |
| first_indexed | 2024-12-17T07:08:37Z |
| format | Article |
| id | doaj.art-053a2174788d4752bef598a3a2fdc22f |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-17T07:08:37Z |
| publishDate | 2021-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-053a2174788d4752bef598a3a2fdc22f2022-12-21T21:59:06ZengElsevierGynecologic Oncology Reports2352-57892021-08-0137100808Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancerE.A. Johns0J.A. Stanley1M.D. Toboni2J.K. Schwarz3F. Zhang4A.R. Hagemann5K.C. Fuh6P.H. Thaker7C.K. McCourt8D.G. Mutch9M.A. Powell10D. Khabele11L.M. Kuroki12Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USADivisions of Clinical and Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivisions of Clinical and Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Clinical Research, Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, USA; Corresponding author at: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Mail Stop 8064-37-905, St. Louis, MO 63110, USA.The role for localized radiation to treat ovarian cancer (OC) patients with locally recurrent vaginal/perirectal lesions remains unclear, though we hypothesize these patients may be salvaged locally and gain long-term survival benefit. We describe our institutional outcomes using intensity modulated radiation therapy (IMRT) +/- high-dose rate (HDR) brachytherapy to treat this population. Our primary objectives were to evaluate complete response rates of targeted lesions after radiation and calculate our 5-year in-field control (IFC) rate. Secondary objectives were to assess radiation-related toxicities, chemotherapy free-interval (CFI), as well as post-radiation progression-free (PFS) and overall survival (OS). PFS and OS were defined from radiation start to either progression or death/last follow-up, respectively. This was a heavily pre-treated cohort of 17 recurrent OC patients with a median follow-up of 28.4 months (range 4.5–166.4) after radiation completion. 52.9% had high-grade serous histology and 4 (23.5%) had isolated vaginal/perirectal disease. Four (23.5%) patients had in-field failures at 3.7, 11.2, 24.5, and 27.5 months after start of radiation, all treated with definitive dosing of radiation therapy. Patients who were platinum-sensitive prior to radiation had similar median PFS (6.5 vs. 13.4 months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months, log-rank p = 0.05) than their platinum-resistant counterparts. Excluding patients with low-grade histology or who were treated with palliative radiation, median CFI was 14.2 months (range 4.7 – 33.0). Radiation was well tolerated with 2 (12.0%) experiencing grade 3/4 gastrointestinal/genitourinary toxicities. In conclusion, radiation to treat locally recurrent vaginal/perirectal lesions in heavily pre-treated OC patients is safe and may effectively provide IFC.http://www.sciencedirect.com/science/article/pii/S2352578921001120Recurrent ovarian cancerLocalized recurrenceOligometastatic recurrenceRadiation |
| spellingShingle | E.A. Johns J.A. Stanley M.D. Toboni J.K. Schwarz F. Zhang A.R. Hagemann K.C. Fuh P.H. Thaker C.K. McCourt D.G. Mutch M.A. Powell D. Khabele L.M. Kuroki Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer Gynecologic Oncology Reports Recurrent ovarian cancer Localized recurrence Oligometastatic recurrence Radiation |
| title | Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| title_full | Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| title_fullStr | Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| title_full_unstemmed | Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| title_short | Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| title_sort | radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer |
| topic | Recurrent ovarian cancer Localized recurrence Oligometastatic recurrence Radiation |
| url | http://www.sciencedirect.com/science/article/pii/S2352578921001120 |
| work_keys_str_mv | AT eajohns radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT jastanley radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT mdtoboni radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT jkschwarz radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT fzhang radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT arhagemann radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT kcfuh radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT phthaker radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT ckmccourt radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT dgmutch radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT mapowell radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT dkhabele radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer AT lmkuroki radiationtherapyforvaginalandperirectallesionsinrecurrentovariancancer |